Showing posts with label London. Show all posts
Showing posts with label London. Show all posts

Monday, 5 March 2018

HTA R Us

Together with colleagues around the UK, we're organising a workshop on the use of R for statistical modelling in health economic evaluation (broadly speaking, "cost-effectiveness analysis").

It's good that this is exciting news (contributing to taking my mind off all the politics & elections in the world...). But I think this really is exciting news, with a very good line up of speakers/talks. And I really think the objectives of this workshop are very interesting $-$ I think, ultimately, we'll aim at also creating a repository for files/examples/models/templates so that people can start using R for their health economic modelling more and more.

Details below $-$ and Howard tells me the spaces are filling up very quickly...

One-day workshop on R for trial and model-based cost-effectiveness analysis
Date: 11th July 2018.
Organizer: Howard Thom, Bristol Medical School: Population Health Sciences, University of Bristol.

It is our pleasure to announce a one-day workshop on the use of R for trial and model-based cost-effectiveness analysis (CEA). CEA is often done using Excel but, despite its ease of use, Excel incurs the disadvantages of slow computational speed and a lack of transparency; our workshop aims to explore the use of R for CEA as an alternative. A wide range of technical aspects, including a discussion of the many available add-on packages, will be presented to help users get the most out of R for CEA. Presentations and public discussions will address the computational and transparency advantages of R over Excel for CEA and for easing collaboration. Our expert speakers have diverse experience in government (including NICE), academia, and industry. There will also be a contributed oral presentation session and a poster session for which we invite  the submission of abstracts. Lunch and refreshments will be provided.  A preliminary programme is below. 

There is no registration deadline, but places are limited so it is recommended to register soon.

To submit an abstract, please send it to howard.thom@bristol.ac.uk with the subject “R for CEA abstract”. The word limit is 300. Please specific whether the abstract is for oral or poster presentation, or if either is acceptable. Note that only 4 oral presentation slots are available. Abstract submission deadline is 15th May and the scientific committee will make decisions on acceptance by 1st June 2018.

If you have any further queries please contact me on howard.thom@bristol.ac.uk

Best wishes,
Howard.

Scientific committee:
Howard Thom. Bristol Medical School: Population Health Sciences, University of Bristol.
Claire Williams. Bristol Medical School: Population Health Sciences, University of Bristol.
Nicky Welton. Bristol Medical School: Population Health Sciences, University of Bristol.
Padraig Dixon. Bristol Medical School: Population Health Sciences, University of Bristol.
Gianluca Baio. Department of Statistical Science, University College London.
Anthony Hatswell. Delta Hat Analytics, UK; Department of Statistical Science, University College London.
Marta Soares. Centre for Health Economics, University of York
Dyfrig Hughes. Centre for Health Economics & Medicines Evaluation, Bangor University
Chris Jackson. Medical Research Council Biostatistics Unit, University of Cambridge
Boby Mihaylova. Health Economics Research Centre, Nuffield Department of Public Health, University of Oxford.
Iryna Schlackow. Health Economics Research Centre, Nuffield Department of Public Health, University of Oxford.

Preliminary Program
9:30-9:45. Howard Thom. Welcome.
9:45-10:15. Gianluca Baio. Department of Statistical Science, University College London.
R you seriously saying we shouldn't use Excel?
This talk will showcase some of the R packages recently developed to aid the work of modellers working in health economic evaluations. The motivation and general philosophy of a few packages will be briefly presented. Examples of their use/advantages over more established, but often non-optimal computational tools, such as MS Excel will be demonstrated.
10:15-11:25. Marta Soares. Centre for Health Economics, University of York
Using R for Markov modelling: an introduction.
This talk introduces the use of R for generic decision modelling detailing some of the advantages and disadvantages of this software package in relation to others commonly used, such as MS Excel. In this talk, I also present generic R code for Markov modelling, probabilistic sensitivity analyses and value of information analyses (using Monte Carlo simulation).
A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
This talk will present the design and structure in R of the SHARP CKD-CVD model, developed using the 5-years follow-up data of 10,000 patients with chronic kidney disease in the SHARP study.  The model projects chronic kidney disease progression and cardiovascular complications and mortality using a set of multivariate risk, cost and QoL equations. We will demonstrate the R Shiny-based model interface to enable use by external analysts and will discuss issues related to model functionality and speed of execution.
11:05-11:20. Coffee
11:20-12:20. Participants oral presentation session (4 speakers, 15 minutes each)
12:20-13:45. Lunch and poster presentations.
13:45-14:00. Dyfrig Hughes. Centre for Health Economics & Medicines Evaluation, Bangor University
Health technology assessors' perspectives on R
This session will present the perspectives of members of NICE evidence review groups, AWMSG secretariat and SMC independent assessors on sponsor submissions using R. The skill requirements, confidence and expertise of these groups in using R will also be discussed.
14:00-14:15. Howard Thom.
Value of information analysis in R.
This session will cover the methods for value of information analysis that can be implemented in R, including linearization, brute force Monte Carlo simulation, parallel computing, meta-modelling, multilevel Monte Carlo and quasi Monte Carlo.
14:15-14:25. Chris Jackson. Medical Research Council Biostatistics Unit, University of Cambridge
Continuous-time multi-state models for disease progression
This session will introduce the theory of modelling disease progression as a continuous-time multi-state process, and how this can be used in cost-effectiveness analysis. R software for continuous-time modelling of various patterns of observed data will be discussed.
14:25-14:45. Claire Williams. Bristol Medical School: Population Health Sciences, University of Bristol.
An overview of a suite of code and functions for CEA in R using continuous-time multi-state modelling
This session will give a brief snapshot of the code already available in a tutorial paper detailing how to carry out Markov and semi-Markov modelling using the continuous-time multi-state modelling survival analysis framework. It will include how to carry out deterministic and probabilistic sensitivity analysis and appropriate graphical outputs.
14:45-15:00. Coffee
Existing frameworks for collaborative working
This session will outline various ways of working currently used in collaborative efforts in the health economics and connected spheres. The pros and cons of each approach will be outlines, and how the use of R may be promoted under each of the scenarios.
15:15-16:30. Participant discussion.

16:30-16:45. Howard Thom. Close and conclusions.

Friday, 2 March 2018

Job advert

We have a job opening at UCL $-$ this time is in the Institute of Clinical Trials & Methodology and is for a Research Associate in Health Economics. Full details below.

Applications are invited for a Research Associate in Health Economics to join the growing number of health economics researchers at UCL and its partner institutions. The post will join the Health Economics Analysis and Research Methodology Team in the Institute for Clinical Trials and Methodology (ICTM) at UCL, working primarily with the Comprehensive Clinical Trials Unit (CCTU).

The post focuses primarily on economic evaluations and decision modelling alongside randomised controlled trials and provides a unique opportunity for a researcher in health economics who would like training and hands on experience of economic evaluations using trial data. The CCTU has a growing portfolio of large, multi-centre randomised control trials in pharmaceutical, surgical and specialist interventions providing the post holder with experience in the design, conduct and analysis of these trials. As a member of the CCTU you will be involved in the health economic components throughout the lifetime of the trial. Training and support will be provided by your colleagues in the Health Economics Analysis and Research Methodology Team to provide you with the skills you need to confidently undertake your role. The post also provides the opportunity for the successful applicant to pursue their own research interests.

For more information or to apply for this role please go to:

Salary: £34,635 to £41,864

The post is for 1 year in the first instance, but with the potential to extend this.

Closing date for applications: 1 April 2018

Wednesday, 21 February 2018

Commonwealth Games

Earlier this week, we found out that we have secured the Commonwealth Share Scholarship for our Master Programme in Health Economics & Decision Science.

The Commonwealth Shared Scholarship Scheme is a joint initiative between the Commonwealth Scholarship Commission (with funding from the Department for International Development (DFID), and UK universities, to support scholarships for students from developing Commonwealth countries who would not otherwise be able to study in the United Kingdom.

The aim of the scheme is to assist students from developing Commonwealth countries who are of excellent academic calibre but for financial reasons would not otherwise be able to afford to study in the United Kingdom. The scheme allows them to benefit from postgraduate study at a university in the United Kingdom which will help them to contribute toward the development of their home countries.

Applicants must:

  • Be a Commonwealth citizen, refugee, or British protected person;
  • Be permanently resident in a developing Commonwealth country (for a full list of eligible countries, see the Commonwealth Scholarships Commission terms and conditions;
  • Be available to start your academic studies in the UK by the start of the UK academic year in September/October 2018;
  • By August 2018, hold a first degree of either first or upper second class (2:1) classification, or lower second class (2:2) classification plus a relevant postgraduate qualification (usually a Master’s degree);
  • Not have studied or worked for one (academic) year or more in a developed country;
  • Be unable, either yourself or through your family, to pay to study in the UK.
More info here.

Tuesday, 6 February 2018

Acro-juggling

Yesterday, we held our UCL Health Economics Network Symposium. 

Kobi has been poorly since Friday, which of course has coincide with a particularly busy week end/start to the new week... Sunday night was particularly bad and we managed to accomplish a trip to A&E (luckily all is good) and some healthy running around so that someone was at home with him at any given time, while teaching and, in fact, going to the Symposium (the picture to the left shows Marta and I practising our acro-juggling...).

Anyway, despite being low on sleep and rather high on coffee, I managed to talk about our work on Bayesian modelling on missing data in health economic evaluation and our research group in general $-$ Anna and Spyros also presented nice posters about their respective work. Copies of the slides that were presented yesterday are also available here.

I think the event (or to be more precise, what I managed to catch of it) was very interesting and we attracted a varied range of people from within and outside academia, which was really one of the main objectives. And I think the plan is to turn this into an annual event.

Sunday, 21 January 2018

PhD studentships @ UCL

My department at UCL has been allocated 1 EPSRC Doctoral Training Partnership (DTP) award for 2018/19. The award will be 4 years in duration (or 6 years for part-time candidates), covering UK/EU fees, minimum RCUK stipend and a small allowance for consumables. To be eligible for the full award a student must have no restrictions on how long they can stay in the UK and have been ordinarily resident in the UK for at least 3 years prior to the start of the studentship.

Marta and I have a joint project on "An integrated Bayesian approach in air pollution and health studies: linking exposure, health and economic evaluation", which is basically a 50:50 mixture of hers and my own signature dishes... Not as fancy as the stuff we've done together in the past $-$ but probably a tiny bit more relevant...

The advert is now live on the UCL website (amongst other places).

Wednesday, 10 January 2018

MSc studentships @ UCL

Two National Institute for Health Research (NIHR) studentships in Medical Statistics are available for the 2018/19 academic year. The studentships cover tuition fees at the UK/EU rate and a maintenance stipend of £17,050 per annum (based on the standard UK Research Council rate with London weighting). All eligible applicants for the MSc Medical Statistics Course will automatically be considered. And: you don't have to be a capricorn...

For further information please contact Dr Russell Evans (russell.evans@ucl.ac.uk)

Wednesday, 27 September 2017

24. Nearly.

As the academic year is beginning (our courses will officially start next week), this week has seen the arrival of our new students, including those in our MSc Health Economics & Decision Science (I've talked about this here and here).

When we set out the planning, we were a bit nervous because, while everybody at UCL has been very encouraging and supportive, we were also given a rather hard target $-$ get at least 12 students, or else this is not viable. (I don't think we were actually told what would have happened if we had recruited fewer students. But I don't think we cared to ask $-$ the tone seemed scary enough)...

Well, as it happens, we've effectively doubled the target and we now have 22 students starting on the programme $-$ there may be a couple more additions, but even if they fail to turn up, I think Jolene, Marcos and I will count ourselves very happy! I've spoken to some of the students yesterday and earlier today and they all seem very enthusiastic, which is obviously very good!

Related to this, we'll soon start our new seminar series, to which all the MSc students are "strongly encouraged" to participate. But I'll post more generally in case they may be of interest to a wider audience...

Thursday, 20 April 2017

Post-doc

If you fancy becoming like the crazy, purple minion, we have a Research Associated position at the UCL Institute for Global Health (with whom I've been heavily involved in the past year or so, while organising our new MSc Health Economics & Decision Science). 

All the relevant details and the link to the application form are available here. The deadline is 13 May.

Tuesday, 18 April 2017

Workshop on The Regression Discontinuity Design

As part of our bid to get an MRC grant (which we managed to do), we promised that, if successful, we'd also have a dissemination workshop, at the end of the project. Well, the project on the Regression Discontinuity Design (RDD) has now finished for a few months, but we're keeping our word and we have actually organised something that, as it happens, has probably turned into something slightly bigger (and better!) than intended...

As I was talking to Marcos (who's a co-director of our MSc programme, which I've mentioned for example here), we realised that the RDD is in fact a common interest of ours and so I jumped on his offer to do something together.

The plan is to have a full day on the 27th June at the Institute of Fiscal Studies in London, with the idea of mixing economists, statisticians and epidemiologists. We have a nice line up of speakers $-$ the original idea was more to show off the outputs of the project, but I think this works much better!

The registration is now open and free $-$ all the relevant information is here!

Friday, 31 March 2017

The greedy baker with a full barrel and a drunken wife

Earlier this week, I gave a talk at one of the UCL Priment seminars. The session was organised around two presentations aimed at discussing the definition and differences between "confidence" and "credible" intervals $-$ I think more generally, the point was perhaps to explore a little more the two approaches to statistical inference. Priment is a clinical trial unit and the statisticians and clinicians involved there mostly (if not almost always) use frequentist methods, but I think there was some genuine interest in the application of Bayesian inference. I enjoyed very much the event. 

For my talk, I prepared a few slides to briefly show what I think are the main differences in the two approaches, mostly in terms of the fact that while in a Bayesian context inference is performed with a "bottom-up" approach to quantify and evaluate $$\Pr(\mbox{parameters / hypotheses} \mid \mbox{observed data})$$ a frequentist setting operates in the opposite direction using a "top-down" approach to quantify and evaluate $$\Pr(\mbox{observed data / even more extreme data} \mid \mbox{hypothesised parameters}).$$
I think that went down well and at the end we got into a lively discussion. In particular, the other speaker (who was championing confidence intervals), suggested that when the two approaches produce results that are numerically equivalent, then in effect even the confidence interval can be interpreted as to mean something about where the parameter is. 

I actually disagree with that. Consider a very simple example, where a new drug is tested and the main outcome is whether patients are free from symptoms within a certain amount of time. You may have data for this in the form of $y \sim \mbox{Binomial}(\theta,n)$ and say, for the sake of argument that you've observed $y=16$ and $n=20$. So the 95% confidence interval is obtained (approximately) as $$\frac{y}{n} \pm 2\,\mbox{ese}\!\left(\frac{y}{n}\right),$$ where ese$(\cdot)$ indicates the estimated standard error for the relevant summary statistics. 

The probabilistic interpretation of this confidence interval is 
$$\Pr\left(a \leq \frac{y}{n} \leq b \mid \theta = \frac{y}{n} \right) = 0.95$$
and what it means is that if you're able to replicate the experiment under the same conditions, say 100 times, then 95 of them the resulting confidence interval would be included between the lower and upper limits $a$ and $b$. With the data at hand, this translates numerically to 
$$\Pr\left(0.6211\leq \frac{y}{n} \leq 0.9788 \mid \theta=0.80\right) = 0.95$$
and the temptation for the greedy frequentist is to interpret this as a statement about the likely location of the parameter.

The trouble with this is that by definition, a confidence interval is a probabilistic statement about sampling variability in the data $-$ not about uncertainty in the parameters as shown in the graph below.
(in this case, in fact 4 out of 100 hypothetical sample means fall outside the confidence interval limits, but this is just random variation).

The "alternative" interpretation, rescales the graph above by using the sample mean to produce the one below.

While this is perfectly valid from a mathematical point of view, however, this interpretation kind of muddies the water, I think, because it kind of confuses the point that this is about sampling variability in the data. And the data you would get to see in replications of the current experiment would be about the observed number of patients free from symptoms, $y^{new} \sim \mbox{Binomial}(\theta=0.8,n=20)$. 

Thus, it is a bit confusing, I think, to say that a Bayesian analysis could yield the same numerical results as the confidence interval $-$ perhaps a more appropriate interpretation would be that this is a probabilistic statement in the form 
$$ \Pr\left(na \leq y \leq nb \mid \theta=\frac{y}{n}\right) = 0.95, $$
which in the present case translates to 
$$ \Pr\left(12.43 \leq y \leq 19.58 \mid \theta=0.8\right) = 0.95, $$
which suggest we should expect to see a number of patients free from symptoms between 12 and 20 in replications of the current experiment (which is of course in line with the first graph shown above, on the scale of the observable data).

The Bayesian counterpart to this analysis may assume a very vague prior on $\theta$, for example $\theta \sim \mbox{Beta}(\alpha=0.1,\beta=0.1)$. This would suggest we're encoding our knowledge about the true probability of being symptoms-free in terms of a thought experiment where $\alpha+\beta=0.2$ patients were observed and only $\alpha=0.1$ were symptoms free (ie a prior estimate of 0.5 with very large variance).

Combining this with the data actually observed $y=16, n=20$, produces a posterior distribution $\theta\mid y \sim \mbox{Beta}(\alpha^*=\alpha+y, \beta^*=n+\beta-y)$, or in this case $\theta \mid y \sim \mbox{Beta}(16.01,4.1)$, as depicted below.


A 95% "credible" interval can be computed analytically and as it turns out it is $[0.6015; 0.9372]$, so indeed very close to the numerical limits obtained above when rescaling to the sample mean $y/n$ $-$ incidentally:
1. It is possible to include even less information in the prior and so get even closer to the frequentist analysis;
2. However, even in the presence of large data that probably will overwhelm the prior anyway, is it necessary to be soooo vague? Can't we do a bit better and introduce whatever prior knowledge we have (which probably will separate out the two analyses)?
3. I don't really like (personally) the term "credible" interval. I think it's actually un-helpful and it would suffice to call this an "interval estimate", which would highlight the fact that given the full posterior distribution, then all sorts of summaries could be taken.

The Bayesian analysis tells us something about the unobservable population parameter given the data we've actually observed. We could predict new instances of the experiment too, by computing
$$ p(y^{new}\mid \theta,y) = \int p(y^{new}\mid \theta)p(\theta\mid y) \mbox{d}\theta. $$
This means assuming that the new data have the same data generating process as those already observed and that we propagate the revised, current uncertainty in the parameter to the new data collection. In some sense, this is even the "true" objective of a Bayesian analysis, because parameters typically don't "exist" and they are just a convenient mathematical feature we use to model observable data.

The confidence interval can make probabilistic statements about the likely range of observable data in similar experiments that we may get to see in the future. The Bayesian analysis tells us something about the likely range of the population parameter, given the evidence observed and our prior knowledge, formally included in the analysis. 

While I think the construction of the confidence interval has some meaning when interpreted in terms of replications of the experiment (particularly with respect to the actual data!), I believe that the stretch to the interpretation as a probability for the parameter is a unwarranted, hence the reference to the greedy baker who wants to have and eat his cake $-$ which in Italian would translate as having a full barrel (presumably of wine) and a drunken wife...

So I guess that, in conclusion, if you enjoy a tipsy partner, you should be Bayesian about it...

Friday, 16 December 2016

Movie stars

Our search for potential alternatives to an academic career, in the face of increasing competition and difficulties in securing grant money has now led Jolene, Marcos and me to seek employment in the show-biz $-$ just in case we fail to recruit enough students for our new MSc in Health Economics & Decision Science...




Thursday, 15 December 2016

PhD opportunity!

Applications are invited for a PhD funding opportunity to conduct research in a branch of probability or statistics based in the UCL Department of Statistical Science, commencing in September 2017. This funding is provided by the Engineering and Physical Sciences Research Council (EPSRC).

The requirement for admission to the MPhil/PhD in Statistical Science is a 1st class or high upper 2nd class Bachelor’s degree, or a Master’s degree with merit or distinction, in Mathematics, Statistics, Computer Science, or a related quantitative discipline. Overseas qualifications of an equivalent standard are also acceptable. Further details can be found on the Departmental website. Applicants are expected to prepare an outline proposal of their work. We have some interesting project in our pipeline, including extensions of our work on survHE, or related to evidence synthesis and network meta-analysis, as well as the use of observational data for health economic evaluation.

The studentship will be four years in duration and covers tuition fees at the UK/EU rate plus a stipend of £16,785 per annum for eligible UK residents. EU nationals who have not been ordinarily resident in the UK for 3 years prior to the start of the studentship may still qualify for a fees only award. The studentship may only be awarded to applicants liable to pay tuition fees at the UK/EU rate (i.e. it cannot be used to part-cover overseas tuition fees). 


Further information, including details of how to apply, is available here.

Wednesday, 23 November 2016

Come & play with us!

We're starting to build up the promotional material for our new MSc in Health Economics and Decision Science. Here's the first of a few videos we've filmed!


Tuesday, 8 November 2016

Lectureship @ UCL

As part of our new MSc in Health Economics and Decision Science, we're recruiting a lecturer $-$ the job advert with all the relevant details are here. The post will be based at the UCL Institute of Global Health, but much as the MSc, the job-holder will work across the three areas of this entire project (IGH, Statistical Science and Economics).

The deadline for application is December 4th and we aim to interview shortly after! Incidentally, working from home should be acceptable...

Monday, 10 October 2016

Masters of some

This is really exciting $-$ well, at least for us... Our new Masters in Health Economics and Decision Sciences is up and running and applications are now open for the next academic year!

We're updating the promotional material (which will also feature a rather embarrassing interview that I and others have filmed to describe the life-changing advantages people will experience if they come and study with us), so I'll point to more (hilarious, but hopefully also helpful) bits as they become available.

In the meantime, we thought we'd include some ideas of what the syllabus might look like, for different students' backgrounds (in brackets the departments/institutes within UCL already providing the module).


Sample module selection for a student with a first degree in Epidemiology or Statistics (or any other quantitative discipline aside from Economics), wishing to take the Decision Science Stream within the degree
1. Health Systems in a Global Context (Institute of Global Health, IGH)
2. Economic Evaluation (IGH) 
3. Medical Statistics I (Statistical Science, Stats)
4. Key Principles of Health Economics
5. Introductory Microeconomics  
6. Modelling for Decision Science
7. Bayesian Methods in Economic Evaluation
8. Medical Statistics II (Stats)


Sample module selection for a student with a first degree in Economics, wishing to take the Decision Science Stream within the degree
1. Health Policy and Reform  (Centre for Philosophy Justice and Health, CPJH)
2. Economic Evaluation (IGH) 
3. Medical Statistics I (Stats)
4. Microeconomics for Health
5. Modelling for Decision Science
6. Bayesian Methods in Economic Evaluation
7. Health Economics (Economics, Econ)
8. Urban Health (IGH)


Sample module selection for a student with a first degree in Epidemiology or Statistics (or any other quantitative discipline aside from Economics), wishing to take the Economic Stream within the degree
1. Health Systems in a Global Context (IGH)
2. Introductory Microeconomics  
3. Econometrics (NEW)
4. Economic Evaluation (IGH) 
5. Microeconomics for Health
6. Health Economics (Econ)
7. Medical Statistics I (Stats)
8. Bayesian Methods in Economic Evaluation


Sample module selection for a student with a first degree in Economics, wishing to take the Economics Stream within the degree
1. Health Policy and Reform  (CPJH)
2. Econometrics (NEW)
3. Economic Evaluation (IGH) 
4. Microeconomics for Health
5. Health Economics (Econ)
6. Modelling for Decision Science (NEW)
7. Bayesian Methods in Economic Evaluation

8. Social Determinants of Health


We've already received some applications, which is super good news $-$ but there's still plenty of room!

Tuesday, 5 July 2016

Fire and mouse alarm

Yesterday we finally had our workshop on infectious disease modelling in health economic evaluation. I think the day went very well and we had very interesting talks (as soon as I can, I will upload the slides on the website above, for all the speakers who can grant us permission to do so).

The morning was the most technical part (as intended), but I think everybody was able to follow the talks (which at times had lots of statistical details), because they all had some practical results and nice graphical displays. 

The "industry" session was also very interesting and quite varied with different perspectives and problems being highlighted. 

Then, just after the start of the final session (which had speakers from NICE and the JCVI, to present the reimbursement agencies perspective), all hell broke lose: first, the fire alarm went off, for what turned out to be basically nothing $-$ I was trying to listen to the conversation between the UCL people and Fire Marshals trying to determine whether there really was a risk and I think I understood that they were getting really annoyed at the alarm going off for what was clearly nothing). 

Then, as we resumed the session, we had another interesting surprise. Shortly after the beginning of the second talk, a little mouse (probably disturbed by all the fuss caused by the fire alarm) decided to start roaming through the lecture theatre. I thought I caught a glimpse of something moving suspiciously while I was listening to the talk, but I made nothing of it $-$ until I saw other people looking away from the lectern and increasingly slightly disgusted... Eventually, the mouse got bored (and possibly scared) of the people and disappeared somewhere in one of the air conditioning holes. But that's Central London for you...

Friday, 17 June 2016

Workshop on Infectious Disease Modelling in Public Health Policy: Current status and challenges (yet, again)

I've written about this a couple of times already (here and here). We've finalised the speakers line up (see here for the latest information) and I think this is a very exciting programme! (I know you may think "well, he would say that, wouldn't he?" $-$ and you're probably right... But I do think that the line up is really interesting!).

Anyway, although the registration list on Eventbrite is formally close, I think we do have some places available $-$ so if you would like to go, send me an email (details on the website)!

Thursday, 21 April 2016

Workshop on Infectious Disease Modelling in Public Health Policy: Current status and challenges (again)

We've had a fantastic response to the workshop. In just a few days of public advertisement (I firstly posted about it and then advertised on allstat and HEALTHECON-ALL) we got 65 registration, as of today. 

We have provisionally set out 100 "tickets" (although the workshop is free). I think we may be able to actually extend this a little and have a few more participants. But the main message is this:


Hurry up!

Wednesday, 13 April 2016

Workshop on Infectious Disease Modelling in Public Health Policy: Current status and challenges

Later this year, we're holding at UCL a workshop on modelling for infectious disease with specific focus on the implications and challenges for health economic evaluation. 

I think this is a very interesting area for all sorts of different reasons: in particular, modelling is generally complex (because infectious disease need to be modelled accounting for population dynamics and interactions). This may have implications in terms of health economic evaluation, because the extra complexity impacts on the possibility/simplicity with which one can perform full probabilistic sensitivity analyses.

The workshop (which will be on 4th July) will try and explore three different perspectives: in the morning, we'll have a discussion from the methodological point of view; we'll try and explore the established analytic methods and the challenges in adapting them to a full economic assessment (as opposed to an epidemiological perspective, which, I think, is where they are established in the first place). 

Then in the afternoon we'll have two sessions exploring the industry and then the regulatory 
perspectives. Again we'll try and discuss the implications and challenges faced when dealing with interventions against infectious diseases, from a public health decision-making point of view. 

More information on the day are available here, while details for registration are here.

Friday, 11 March 2016

Short course on Statistical Methods for the Value of Information Analysis

We're now ready to start the advertisement for our short course on Statistical Methods for the Value of Information Analysis (I've posted about this here). The course will be at UCL from the 8th to the 9th of June, later this year. I think we have been lucky to secure some funding and so it will be relatively cheap $-$ it's also conveniently a week before the SMDM conference, so we're hoping that some people may be travelling to London a little earlier to join us!

The first day will be much less technical and applied and in fact we are allowing a larger number of participants (up to 70) $-$ I think this may be interesting to people working in health economics and regulatory agencies, as well as those leading in trials designs and implementation. The second and third day will be much more technical and applied (that's why we are considering a maximum of 30 participants) and we'll have lots of computer practicals. I think these two days will be of more interest to statisticians and modellers.

Anna has made a very nice flyer which contains all the relevant information. But I'm also copying this right here:

Course Title: Statistical Methods for Value of Information Analysis
Course Dates: 8th - 10th June 2016
Course Location: University College, London

Course Lecturers:
Gianluca Baio (University College London)
Anna Heath (University College London)
Mark Strong (University of Sheffield)
Nicky Welton (University of Bristol, ConDuCT-II Hub for Trials Methodology Research)

Cost: 
For 3 days: £300 (£150 for students)
For the 1st day only: £100 (£50 for students)
For 2nd and 3rd days: £200 (£100 for students)

This course is subsidised by MRC Network of Hubs for Trials Methodology Research and UCL. Travel bursaries are also available for students and hub network members, courtesy of the MRC Network of Hubs for Trials Methodology Research. To apply, contact g.baio@ucl.ac.uk. Two free places available per hub.

Registration: Registration is open, please visit the UCL online store 

Places available: 70 for Day 1; 30 for Days 2 and 3.

Course Description:
Day 1, 9:30 – 16:30: 

  • The interpretation of results from a probabilistic approach to cost-effectiveness analysis
  • The interpretation of the expected value of perfect information (EVPI), expected value of partial perfect information (EVPPI) and expected value of sample information measures
  • Possible uses of EVPPI for research prioritisation and adoption/reimbursement decisions
  • Potential use of EVSI for designing new research studies

This day will be an introduction to value of information and has no pre-requisites. This day can be taken as a stand-alone course.

Day 2, 9:00 – 16:30:

  • Simple probabilistic cost-effectiveness analysis in R, using the BCEA package
  • Simulation approaches to the computation of EVPI and EVPPI, and computation using R
  • Algebraic tricks that can be used to reduce computational burden of EVPPI, calculation using R
  • The computational challenges for EVPPI and EVSI

This day will be a mixture of lectures and computer practical. Therefore, some knowledge of computer programming is preferable, ideally in R. Knowledge of value of information methods (or attendance to Day 1) are necessary.

Day 3, 9:30 – 16:15:

  • Meta-modelling approaches for the computation of EVPPI 
  • The SAVI Web App for computation of EVPPI
  • The R package BCEA for computation of EVPPI

This day follows from Day 2 and again will be a mixture of lectures and computer practicals.


Who should attend: Anyone with interest in VoI methods and their application in Health-Economic Evaluations.